Isolated del(5q) with myeloproliferative driver mutations: A systematic review of published cases and clinical implications
Therapeutic Advances in Hematology · 2026-07 · 17
DOI: 10.1177/20406207261474937 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Hematology, online erschienen am 17.08.2026. Verfasst von Mohammed Abdulgayoom und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Hamad Medical Corporation, National Center for Cancer Care and Research, Doha, Qatar. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Qatar National Library.
Abstract (Originalsprache)
Background
Myeloid neoplasms harboring both an isolated deletion of chromosome 5q (del(5q)) and myeloproliferative neoplasm (MPN) driver mutations ( JAK2, CALR, MPL ) constitute a rare and diagnostically challenging subset, often described with features overlapping those of myelodysplastic syndromes (MDS) and MPN.
Methods
We systematically reviewed published case reports and case series of adult patients with myeloid neoplasms and concomitant isolated del(5q) and MPN driver mutations. A comprehensive search of PubMed and Google Scholar from inception through 31 December 2024 was performed using terms related to “del(5q)”, “ JAK2”, “CALR”, “MPL” , and “myeloid neoplasm”. Eligible reports required documentation of isolated del(5q) and at least one MPN driver mutation with extractable clinical, cytogenetic, and/or molecular data. Data were synthesised descriptively; no quantitative meta-analysis was feasible. The review followed PRISMA 2020 guidelines and was registered post-study at INPLASY2025120046.
Results
Twenty publications reporting 24 patients (diagnosed between 2006 and 2021) met the inclusion criteria. The median age was 70.5 years with a female predominance. Most patients presented with macrocytic anemia, thrombocytosis, and megakaryocytic dysplasia, frequently accompanied by marrow fibrosis. JAK2 V617F was the predominant mutation, whereas CALR and MPL were rarely described. Lenalidomide achieved hematologic responses in 14 of 17 evaluable patients and cytogenetic responses in 8 of 16; JAK2 V617F clearance occurred in 4 of 13. During a median follow-up of approximately two years, 5 of 24 patients progressed to acute myeloid leukemia.
Conclusion
Reported cases with isolated del(5q) and an MPN driver mutation suggest a rare overlap presentation with mixed dysplastic and proliferative features. Lenalidomide appears to provide hematologic and cytogenetic benefit in some patients, although molecular persistence and progression to AML have been observed. Given the limited number and heterogeneity of published cases, these observations should be interpreted with caution. Larger, systematically collected datasets are needed to better understand the clinical significance and optimal management of this combination.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, Hamad Medical Corporation, National Center for Cancer Care and Research, Doha, Qatar.
- College of Medicine, Omdurman Islamic University, Khartoum, Sudan.
ORCID-Profile: Mohammed Abdulgayoom, Abdulrahman F Al-Mashdali, Awni Alshurafa, Mohamed A Yassin
Förderung
- Qatar National Library
Zitieren
APA
Abdulgayoom, M., Al-Mashdali, A. F., Alshurafa, A., Afana, M. S., Babiker, A. M., Bakheet, M., Mohamed, S. F., & Yassin, M. A. (2026). Isolated del(5q) with myeloproliferative driver mutations: A systematic review of published cases and clinical implications. Therapeutic Advances in Hematology, 17. https://doi.org/10.1177/20406207261474937
Vancouver
Abdulgayoom M, Al-Mashdali AF, Alshurafa A, Afana MS, Babiker AM, Bakheet M, et al. Isolated del(5q) with myeloproliferative driver mutations: A systematic review of published cases and clinical implications. Therapeutic Advances in Hematology. 2026;17. doi:10.1177/20406207261474937
BibTeX
@article{Abdulgayoom2026,
author = {Abdulgayoom, Mohammed and Al-Mashdali, Abdulrahman F and Alshurafa, Awni and Afana, Mohammad S and Babiker, Anas M and Bakheet, Mohammad and Mohamed, Shehab F and Yassin, Mohamed A},
title = {Isolated del(5q) with myeloproliferative driver mutations: A systematic review of published cases and clinical implications},
journal = {Therapeutic Advances in Hematology},
year = {2026},
volume = {17},
doi = {10.1177/20406207261474937}
}
EUVIMED